Skip to search formSkip to main contentSkip to account menu

S 2209

Known as: S-2209, S2209 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Use of tuberculin skin test, chest radiograph and interferon-gamma release assay to select migrants for treatment of latent tuberculosis.
Australian guidelines recommend the tuberculin skin test (TST) as the preferred test for latent tuberculosis infection (LTBI… 
2009
2009
The peptide‐semicarbazone S‐2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells
Bortezomib is the first approved member of a new class of anti‐myeloma agents, the proteasome inhibitors. Further proteasome… 
2008
2008
The novel non-boronic proteasome inhibitor S-2209 induces apoptosis and growth arrest in multiple myeloma cells
2007
2007
S-2209, a Novel, Non-Boronic Proteasome Inhibitor, Induces Apoptosis and Cell Growth Arrest in Multiple Myeloma Cells.
Purpose: Multiple Myeloma (MM) is still an incurable disease. Patients become resistant to cytotoxic drugs and die of disease… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)